Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)

Clinical Cancer Research

Volumn 21, Issue 1, 2015, Pages 123-133

  Uppal, Hirdesh ^a,b   Doudement, Estelle ^a   Mahapatra, Kaushiki ^a   Darbonne, Walter C ^a   Bumbaca, Daniela ^a   Shen, Ben Quan ^a   Du, Xiaoyan ^a,c   Saad, Ola ^a   Bowles, Kristin ^a   Olsen, Steve ^a,d   Phillips, Gail D Lewis ^a   Hartley, Dylan ^a,e   Sliwkowski, Mark X ^a   Girish, Sandhya ^a   Dambach, Donna ^a   Ramakrishnan, Vanitha ^a  

^a GENENTECH INC   (United States)

^b Department of Oncology Biomarker Development Development Sciences Genentech Inc ^*  (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d ASTRAZENECA   (United Kingdom)

^e ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; DUAL SPECIFICITY PHOSPHATASE 2; FC RECEPTOR; FIBRINOGEN RECEPTOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUBULIN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAYTANSINE; MONOCLONAL ANTIBODY;

ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MEGAKARYOCYTE; MICROFILAMENT; PLOIDY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; THROMBOCYTE RICH PLASMA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MEGAKARYOCYTES; PLATELET ACTIVATION; PLATELET-RICH PLASMA; RECEPTOR, ERBB-2; THROMBOCYTOPENIA;

EID: 84920521262     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2093     Document Type: Article

References (30)

1. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107.
2. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
3. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and ef ficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56.
4. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012;11:1133-42.
5. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013;31:1157-63.
6. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
7. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:3234-41.
8. Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized, open-label, phase 3 trial. Lancet Oncol 2014;15:689-99.
9. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704.
10. Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, et al. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2012;70:591-601.
11. Bühring HJ, Sures I, Jallal B, Weiss FU, Busch FW, Ludwig WD, et al. The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood 1995;86:1916-23.
12. Ramakrishnan V, Reeves PS, DeGuzman F, Deshpande U, Ministri-Madrid K, DuBridge RB, et al. Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. Proc Natl Acad Sci U S A 1999;96:13336-41.
13. Thon JN, Devine MT, Jurak Begonja A, Tibbitts J, Italiano JE Jr. High-content live cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 2012;120:1975-84.
14. Wu Z, Markovic B, Chesterman CN, Chong BH. Characterization of Fc gamma receptors on human megakaryocytes. Thromb Haemost 1996;75:661-7.
15. Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets. Blood 2008;112:2780-6.
16. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001;276:6591-604.
17. Chizzonite R, Truitt T, Podlaski FJ, Wolitzky AG, Quinn PM, Nunes P, et al. IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J Immunol 1991;147:1548-56.
18. Sosabowski JK, Mather SJ. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nat Protoc 2006;1:972-6.
19. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012;69:1229-40.
20. Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011;208:2017-31.
21. Boswell CA, Bumbaca D, Fielder PJ, Khawli LA. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J 2012;14:612-8.
22. Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am 2007;21:685-96.
23. Zeuner A, Signore M, Martinetti D, Bartucci M, Peschle C, De Maria R. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res 2007;67:4767-73.
24. van den Bemt PM, Meyboom RHB, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf 2004;27:1243-52.
25. Zhi H, Rauova L, Hayes V, Gao C, Boylan B, Newman DK, et al. Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo. Blood 2013;121:1858-67.
26. Hunt P, Zsebo KM, Hokom MM, Hornkohl A, Birkett NC, del Castillo JC, et al. Evidence that stem cell factor is involved in the rebound thrombocytosis that follows 5-fluorouracil treatment. Blood 1992;80:904-11.
27. Yoo ES, Ryu KH, Park HY, Seong CM, Chung WS, Kim SC, et al. Myeloid differentiation of humancord blood CD34+ cells during ex vivo expansion using thrombopoietin, flt3-ligand and/or granulocyte-colony stimulating factor. Br J Haematol 1999;105:1034-40.
28. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010;2:17ra9.
29. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008;7:2517-27.
30. Girish S, Li C. Clinical Pharmacology and assay considerations for characterizing pharmacokinetics and understanding efficacy and safety of ADCs. Future Science Ltd; 2014.